#Cadila Healthcare conducted their conference call yesterday for Q4 FY2021
"Cadila is 2nd larget growing company in Pharma space"
Here are the key takeaways π
"Cadila is 2nd larget growing company in Pharma space"
Here are the key takeaways π
Business Updates:
β’ India business grew 20% (includes human health, consumer wellness, & animal wellness)- 16.4BilRs.
β’ US (generic and Sepciality)- 16.03Bill Rs. QoQ decline
β’ Emerging Market growth- 11%: 2.93BilRs Sales.
β’ Launched 7 new product and approvals of 9 product.
β’ India business grew 20% (includes human health, consumer wellness, & animal wellness)- 16.4BilRs.
β’ US (generic and Sepciality)- 16.03Bill Rs. QoQ decline
β’ Emerging Market growth- 11%: 2.93BilRs Sales.
β’ Launched 7 new product and approvals of 9 product.
Revenue Mix:
β’ Human Health (India)- 21% growth (YoY).- 11.04BilRs
β’ Branded Generic Business grew 24% YoY
β’ Gained market share in Pain Mgmt, Anti-Effective, Anti-Diabetic.
β’ Market Share in Gyno, Pain Mgmt, Respiratory was maintained.
β’ Animal Health- 17% growth.
β’ Human Health (India)- 21% growth (YoY).- 11.04BilRs
β’ Branded Generic Business grew 24% YoY
β’ Gained market share in Pain Mgmt, Anti-Effective, Anti-Diabetic.
β’ Market Share in Gyno, Pain Mgmt, Respiratory was maintained.
β’ Animal Health- 17% growth.
New Product and Completion:
β’ 71 filling for injectable products, and cumulative filing is 56 product.
β’ Phase 3 of ZyCoV-D vaccine will the going on.
β’ Completed Phase 2 B Trial of Desidustat in Mexico.
β’ Completed the Phase 3 trial of TD Vaccine in India.
β’ 71 filling for injectable products, and cumulative filing is 56 product.
β’ Phase 3 of ZyCoV-D vaccine will the going on.
β’ Completed Phase 2 B Trial of Desidustat in Mexico.
β’ Completed the Phase 3 trial of TD Vaccine in India.
Vaccine:
β’ Phase 3 Trial- Readout is based on no of event- 158.
β’ Co. expect read out in Q1 of FY2022.
β’ Investment in Vaccine is from internal plans around 150-200 cr.
β’ Plant is currently use for vaccine only.
β’ Phase 3 Trial- Readout is based on no of event- 158.
β’ Co. expect read out in Q1 of FY2022.
β’ Investment in Vaccine is from internal plans around 150-200 cr.
β’ Plant is currently use for vaccine only.
US Business:
β’ Decline was due to delay of orders. There is no reduce in market share.
β’ Next quarter is expected to grew well.
β’ Planning for 40+ new launches of which 8-10 products are high value for next year.
β’ Decline was due to delay of orders. There is no reduce in market share.
β’ Next quarter is expected to grew well.
β’ Planning for 40+ new launches of which 8-10 products are high value for next year.
Remdesivir:
β’ There is no stock return, and remdesivir growth is growing well.
β’ Sales are growing down as case are going down.
InLicense:
β’ InLicensed 16 products. Most of the product is complex products. Major part is injectable. Complex Carbohyrdrate API sort of products.
β’ There is no stock return, and remdesivir growth is growing well.
β’ Sales are growing down as case are going down.
InLicense:
β’ InLicensed 16 products. Most of the product is complex products. Major part is injectable. Complex Carbohyrdrate API sort of products.
Expenses:
β’ Co. don't expects expense coming back to pre-covid level, as co. has taken various initiatives. There would be bit increase in cost, but no till pre-covid level.
β’ 1% margin improvement is expected with digital adoption.
Moraiya Plant: No updates as of now.
β’ Co. don't expects expense coming back to pre-covid level, as co. has taken various initiatives. There would be bit increase in cost, but no till pre-covid level.
β’ 1% margin improvement is expected with digital adoption.
Moraiya Plant: No updates as of now.
PBC and NASH
β’ PBC has higher chance of getting approval, while Nash approval is difficult to comment as of now.
β’ PBC 3rd phase is expected to get approved.
β’ NASH is expected to file in end of 24.
β’ PBC has higher chance of getting approval, while Nash approval is difficult to comment as of now.
β’ PBC 3rd phase is expected to get approved.
β’ NASH is expected to file in end of 24.
Anemia:
β’ Company has completed enrollment, and Cadila expects first co. to get approved as oral due for Anemia for CKD and Non CKD patient.
β’ Market size is more than 100 cr.
β’ In China has tied with CMS and big market over there as well.
β’ Company has completed enrollment, and Cadila expects first co. to get approved as oral due for Anemia for CKD and Non CKD patient.
β’ Market size is more than 100 cr.
β’ In China has tied with CMS and big market over there as well.
Saroglitazar:
β’ Product has done extreme well and there is 1 Million patient.
β’ Co. expects double digit growth.
β’ Tied up with co. such as Gastro and is expected to be block-buster drug.
β’ Still not the top 20 drug.
β’ Product has done extreme well and there is 1 Million patient.
β’ Co. expects double digit growth.
β’ Tied up with co. such as Gastro and is expected to be block-buster drug.
β’ Still not the top 20 drug.
CAPEX:
β’ 700-800 cr target in next year and was same last year.
Flu Vaccine:
β’ Cadila is the only co. which has got the vaccine and this may grow well.
Tax rate: Around 21-22%.
β’ 700-800 cr target in next year and was same last year.
Flu Vaccine:
β’ Cadila is the only co. which has got the vaccine and this may grow well.
Tax rate: Around 21-22%.
For more discussion on Equity research and OI analysis
Subscribe to our YouTube channel π
Link π: youtube.com/c/TheTycoonMinβ¦
Subscribe to our YouTube channel π
Link π: youtube.com/c/TheTycoonMinβ¦
β’ β’ β’
Missing some Tweet in this thread? You can try to
force a refresh
γ
